Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Second Quarter 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Tim Lee, Cerus' Head of Investor Relations. Tim, you may now begin.

Thank you, Tim, and good afternoon, everyone. I would like to open the call with a review of the highlights from the second quarter as well as our outlook for the duration of the year. As we continue to grow our business and advance our complete INTERCEPT product portfolio, I'm very happy to report to you all today another quarter of both solid commercial and product development execution. Guided by our mission to fundamentally transform the safety and availability of transfused blood components, we are realizing a growing foundation of clinical evidence that is helping to establish the INTERCEPT Blood System as the standard of care in transfusion medicine in many countries around the world. The strong revenue growth we experienced during the first quarter continued through Q2, delivering record quarterly sales for the company and a near doubling of our IFC revenue quarter-over-quarter. In fact, our IFC revenue for the first half of 2025 nearly surpassed the full year IFC revenue for 2024. As a result, we are increasingly confident in our ability to exceed our full year 2025 product revenue guidance that we outlined in January. Accordingly, we are raising our full year 2025 product revenue guidance to a range of $200 million to $203 million from our previous range of $194 million to $200 million. While we are seeing growth across our entire INTERCEPT product offering and in each region, the increase in our full year revenue guidance range is largely driven by increasing customer demand for IFC. Its ready availability and positive impact on the complex hospital operations required to manage critically bleeding patients are being acknowledged across the U.S. broadly. Vivek will provide additional color on the exciting growth in our U.S. IFC business in his prepared remarks. Our core platelet franchise continues to be a key driver for revenue growth as well, both in the U.S. and abroad. In the U.S., we are expecting increasing adoption of pathogen-reduced platelets as hospital demand for 100% pathogen-inactivated platelet inventory increases because of the benefits associated with managing the logistics and inventories for platelet transfusion. In international markets, we continue to have a dialogue with many regulators, national blood services, and large blood centers about global platelet safety standards and the important technological role that INTERCEPT can play. Our portfolio of products, including our next-generation illuminators, the INT200, were recently showcased at the International Society of Blood Transfusion Congress in Milan. Having received CE Mark at the end of the first quarter, this Congress served as a great forum to launch the product and to introduce it to our customers as well as our global distribution partners. Feedback on the INT200 continues to be very positive. We have begun deploying the first of these devices in the field and expect that the device will be a foundational component of blood center operations. We are now approved for commercial sale in approximately 40 countries, and the launch allows for new opportunities to engage with blood center customers and reinforces Cerus' innovation in the field of transfusion medicine. Switching to our red blood cell program. In Europe, as we announced last month, the regulatory review is advancing ahead of plan. TŰV SŰD, our notified body, has completed their review of several modules of the submission, including the clinical module, and transferred the dossier to the State Institute for Drug Control, SÚKL, in the Czech Republic for consultation. SÚKL, our competent authority, has started the review of the active pharmaceutical ingredient or API. The clinical module included the positive results from the Phase III ReCePI clinical trial, thereby expanding our CE Mark submission to cover all patient indications for red cell transfusion. The previous submission focused only on the chronic transfusion indication. We are looking forward to working collaboratively with both TŰV SŰD and SÚKL to facilitate the completion of the review process and expect a CE Mark approval decision in the second half of 2026. We also recently just announced a significant award of $7.2 million from the U.S. Defense Department for the funding of a 4-center study called CRYO-FIRST that will evaluate the utility of early IFC in the treatment of major bleeding events in trauma patients. This study is meant to be a pilot clinical study for the future clinical development of a lyophilized version of IFC for potential use in pre-hospital and regional hospital trauma care. We believe that the data from CRYO-FIRST will have potential future utility in defining the clinical benefits associated with early access to fibrinogen. Last but not least, switching to our financials, we continue to execute against our stated goals and remain steadfast in our goal to once again achieve positive non-GAAP adjusted EBITDA. Kevin will provide additional details on this and our full financial results in his prepared remarks. With that, I would now like to turn the call over to Vivek to discuss our second quarter commercial results, along with color on our outlook for 2025.

Thank you, Obi, and good afternoon, everyone. As Obi mentioned, we delivered another strong quarter of commercial execution in Q2. Our record product revenue underscores the progress we are making across multiple geographies and throughout our INTERCEPT product portfolio. Product revenue growth of 16% for the second quarter was driven primarily by increasing customer demand for INTERCEPT's fibrinogen complex as well as continued platelet sales growth in both the U.S. and EMEA region. ISV demand continues to increase, reinforcing the growing adoption of this novel product as hospitals and clinicians gain confidence in its clinical and operational benefits. Regionally, we saw solid momentum across EMEA, where deeper platelet penetration, incremental plasma contribution and the launch of the INT200 Illuminator all contributed meaningfully to solid first half results. Canadian Blood Services has now fully transitioned to 100% routine use of INTERCEPT platelets, and we continue to expand our footprint in the Middle East with Saudi Arabia, Kuwait and the UAE leading platelet growth so far this year. On the plasma side, Red Cross Flanders and Madrid selected INTERCEPT to replace a competing pathogen reduction technology, further validating the strength of our franchise. The INT200 Illuminator continues to resonate with customers and regulators alike. In addition to its CE Mark approval, the device is now approved in France by the Anthem and in Switzerland by Swissmedic. We successfully launched INT200 during the quarter and have been receiving highly encouraging feedback from customers regarding its operational efficiency and user-friendly design. In Germany, the Paul-Ehrlich-Institut, the National Agency regulating blood components, is considering new requirements to further minimize the risk of transfusion-transmitted bacterial infections. These measures may include mandatory implementation of pathogen reduction and/or bacterial testing for all blood units similar to the FDA's bacterial safety standards in the U.S. While this process is still ongoing, we believe that such a regulatory shift could create a positive environment for broader INTERCEPT platelet adoption in Germany over time. In China, the NMPA requested additional pathogen inactivation and in vitro platelet quality data tailored to local processing requirements for our submission. We believe that providing this China-specific data will strengthen our submission and better support market adoption at launch. As a result, the decision was made to withdraw the current submission temporarily in order to generate and include this new data set. China remains a very compelling market opportunity for INTERCEPT and there's a high degree of clinical interest in this product. Turning to the U.S. In the second quarter, we continued to build strong clinical advocacy for INTERCEPT fibrinogen complex with leading physicians from the University of Virginia and Vanderbilt University presenting their early adopter experience at major U.S. medical conferences. At the Society of Cardiovascular Anesthesiologists, Dr. John McNeil highlighted how IFC is being rapidly integrated into cardiac surgery workflows, enabling platelet and IFC delivery within minutes across both pediatric and adult populations. At the Society for Obstetric Anesthesia and Perinatology, Vanderbilt physicians shared compelling interim data showing IFC's role in avoiding unnecessary massive transfusion protocol activation in postpartum hemorrhage, reducing blood component utilization and eliminating wastage. These real-world insights are accelerating awareness and confidence among key clinical specialties, reinforcing IFC's potential to redefine transfusion support in critical care settings. For those of you interested in learning more about these presentations, a recording of Dr. McNeil's presentation is available under the Resources section of the website at www.intercept-usa.com. Beyond the U.S., we maintained a strong international presence, engaging transfusion leaders at national seminars in Switzerland, Austria, Canada, and Spain, and also at the ISBT Regional Congress in Milan. As Obi previously mentioned, at the ISBT Congress, we had an opportunity to introduce the market to our new INT200 Illuminator and showcased extensive scientific data on INTERCEPT platelets, ISC, and red cell programs, underscoring our commitment to advancing blood safety and operational efficiency. These targeted educational initiatives are designed to strengthen our brand, expand our reach within transfusion medicine communities and support growing demand for INTERCEPT-treated blood components. Looking ahead to our future growth prospects, we believe IFC will remain a key driver for Cerus for years to come. We also believe our platelet franchise has significant runway with continued adoption in the U.S., deeper penetration in existing international markets, and opportunities to open up new international geographies. Taken together, this quarter's results and the operational milestones we've achieved give us confidence that the growth trajectory we are on is sustainable. While we remain mindful of macroeconomic and geopolitical factors, the durability of our value proposition and the breadth of our pipeline position us well to continue delivering meaningful innovation and expanding access to safer blood products worldwide. With that, I'll now turn it over to Kevin to walk through our financial results and outlook in more detail.

Thanks Vivek. Hello, everyone. Thank you all for joining us. On today's call, I'll be discussing our financial results for the second quarter of 2025, our increased full year product revenue guidance, and providing some thoughts on our key metrics as we close out the first half and move into the back half of the year. With the exception of revenue, I'll be limiting my commentary on historical results to Q2 rather than year-to-date results. So I'll start off with product revenue. For the second quarter of 2025, we reported product revenue of $52.4 million, translating to a 16% year-over-year increase. For the full first half, product revenue increased 15% to $95.7 million compared to the first half of 2024. IFC sales in the U.S. as well as global platelet sales were the principal drivers of product revenue growth this quarter. Breaking down product revenues by geography, we see that second quarter North American product revenues increased 17% compared to the same period from the prior year. Second quarter EMEA product revenues increased 21% compared to the same period last year due in part to the strength in Middle Eastern platelet sales and expansion of our plasma business from historical platelet accounts. On a non-GAAP basis, excluding the impact of foreign currency exchange rates, EMEA product revenue increased 15%. As we look ahead, we expect that the launch of our LED illuminator in Europe, which kicked off at the end of the first quarter will add to EMEA's growth. IFC product revenue for the second quarter was $5.6 million compared to $2 million during the prior year period. We did recognize approximately $800,000 of previously deferred IFC revenue during Q2. Our IFC product revenue is strengthening from increasing customer demand and product availability. With the production capacity currently available, we expect we will be able to supply the anticipated growth in demand for the back half of the year. Based on our strong year-to-date commercial execution and increasing conviction in our growth projections, we are raising our full year 2025 product revenue guidance range to $200 million to $203 million compared to our previous guidance range of $194 million to $200 million. Included in that, we now expect full year 2025 IFC sales to be in a range of $16 million to $18 million compared to our previous guidance range of $12 million to $15 million. In the near term, we continue to expect increasing IFC revenue to be a key contributor to our overall growth. Beyond product revenue and not included in our guidance, government contract revenue for the second quarter of 2025 was $7.7 million compared to $5.4 million for the prior year period. Enrollment in our RedeS trial as well as the commencement of new activities covered under our BARDA contracts drove the increase in government contract revenue. While we continue to be actively engaged with our government sponsors, we are seeing some impact from the ongoing changes in Washington, including back-office administrative delays and the timing of award modifications. Turning now to our product gross profit and gross margins. Our second quarter product gross profit was $29 million compared to $24.7 million during the prior year period, an increase of 17% year-over-year. Product gross margins for the second quarter were 55.2%, comparable to the 54.7% realized during the second quarter of the prior year. A number of offsetting factors drove the relatively stable margins. Economies of scale with increased volumes, FX rates, and higher ASPs provided a tailwind, while inflation and product mix tempered those factors. As we look ahead to the balance of the year, we expect product gross margins will generally remain in the mid-50s, but face some potential modest headwinds such as foreign exchange rates. Other factors that could drive quarterly variability include, but are not limited to, product mix, production costs of IFC to meet increasing demand, economies of scale and production volumes, and the timing of COGS reduction initiatives coming online. Moving down the income statement. Operating expenses for the second quarter totaled $40.1 million compared to $33.9 million for Q2 2024. Of the total operating expenses reported for the second quarter, R&D expenses totaled $18.9 million compared to $15 million during the prior year. The year-over-year increase in R&D expenses was primarily related to higher development costs of the INT200, higher government contract costs, which in turn drove the increased government contract revenue, and higher employee compensation costs driven by the cost of living adjustments that became effective earlier in the year. SG&A expenses for the first quarter were $21.2 million compared to $19 million in Q2 of 2024. The year-over-year increase in SG&A expenses reflects the cost of living adjustments for our employees as anticipated and noted during our Q1 call. As with the past several years, we are driving the business forward with increasing levels of leverage from our SG&A investments. We expect that the second half of the year will see more of this dynamic, which is central to our strategic business model. Shifting our focus to the bottom line and non-GAAP adjusted EBITDA results. On the bottom line, for Q2 2025, net loss attributable to Cerus was $5.7 million, or $0.03 per share and essentially flat compared to the second quarter of 2024. On a non-GAAP adjusted EBITDA basis, we are pleased to report our fifth consecutive quarter of positive non-GAAP adjusted EBITDA totaling $935,000 for the second quarter compared to $779,000 for the prior year period. We remain steadfast in our goal of achieving full year positive adjusted EBITDA and expect expansion of gross profit, stability of OpEx and importantly, expanding leverage from our SG&A investments will all contribute to achieving this objective. Turning to the balance sheet and associated cash flows. We ended the second quarter with $78 million of cash, cash equivalents, and short-term investments on hand compared to $80.5 million at the end of 2024. As you can see, we've continued to manage the growth in our business with a stable cash balance supported by our growing operations. Cash used from operations increased slightly on a sequential basis to $2.4 million. This was anticipated and was driven by investments in working capital, namely inventory to support expected growth and an increase in our accounts receivable due to administrative delays and timing of payments from the U.S. government for our development contracts. Despite the modest net use of operating cash and working capital investments, we believe we are still in a position to deliver annual positive operating cash flow to fuel our growth going forward. Furthermore, we expect to have increasing access to our revolving line of credit should we choose to further use that facility to offset receivable or inventory-related working capital investments.

Thank you, Kevin. The strong commercial results and progress in product development that we announced today has allowed us to deliver one of the strongest quarters in the company's history. We delivered $52 million in quarterly product revenue, led by robust IFC sales. We raised our full year 2025 product revenue guidance due to expected continued revenue growth, and we realized our fifth consecutive quarter of positive non-GAAP adjusted EBITDA. I'd like to express my deep gratitude to the Cerus team and our blood center partners around the globe for their steadfast commitment to improving blood safety and availability for patients and enabling the INTERCEPT Blood System to become the standard of care in many countries. With more than 20 million INTERCEPT-treated components transfused into patients now, the scale of our impact daily on the field of transfusion medicine is really remarkable and expected to increase meaningfully by the end of the decade. The recent launch of our INT200 LED Illuminator facilitating an unconstrained platform placement, the continued progress of our IFC business, and the anticipated regulatory approval of our INTERCEPT red blood cell program in Europe are expected to deepen our relationships with our existing and future customers. With that, let me turn it over to the operator for questions.

The first question comes from the line of Josh Jennings of TD Cowen.

This is Eric on for Josh. Maybe to start on revenue guidance for the year. That was a great update with the raise. I was just wondering if you could touch on the expected cadence of revenue through the remainder of the year. Maybe should we perhaps look at 2024 as a precedent? Just curious there.

Yes. Thanks a lot, Eric. Kevin, do you want to handle that?

Sure. We expect, obviously, as implied by our revenue guidance, continued growth in the back half of the year relative to the first half. What we've seen historically in EMEA, and I think that will play out again, is somewhat of a flattening from Q2 to Q3, just given the summer holiday season. And then as we pointed out in the prepared remarks, we did have some deferred revenue that was recognized in Q2 that obviously won't be recognized in the back half of the year. So we expect that, again, we'll see growth, but it will be somewhat tempered in Q3. And then historically, we've seen a pretty robust jump in Q4.

Okay. That's helpful. And then maybe looking at the EU red blood cell opportunity, with the expanded CE Mark submission that you have now to cover all patient indications for red blood cell transfusion, is there a way to possibly quantify how that changes the way you're viewing the TAM that you could be addressing relative to that initial submission for chronic transfusion patients?

Yes. Thanks a lot, Eric. I'll take that. And I think basically, what we saw when we were going through the initial indication for just chronic transfusion recipients was that there would be a period of time in which we have sort of a mandatory HP requirement. In discussions right now with TUV, still TBD, but it looks like that is no longer a requirement, and we'd be able to access all patient populations receiving red cell transfusion. So as we sort of think about the initial years post CE Mark approval, it just opens up all the opportunity to us and has fewer restrictions on the blood centers from how they choose to operate. So I think that's still TBD as far as how we'll roll the product out and then evolve the product offering post approval. But it is a welcomed reprieve, if you will, on sort of what the initial limitations would be on the launch.

The next question comes from Ross Osborn of Cantor Fitzgerald.

This is Matt Park on for Ross today. I guess starting with the IFC guide. Given the strong ramp in the first half and the increased guidance, can you walk us through the key drivers in hitting the revised guide? If I'm not mistaken, the updated range implies a slight deceleration half-over-half at the midpoint. Just trying to better understand the puts and takes as we think about quarterly cadence.

Thanks for the question, Matt. Vivek, do you want to handle this?

Sure, I'd be happy to. As Kevin indicated earlier on the call, we had some catch-up in the first half of the year associated with burning through some of the backlog and back orders we had that really started in the end of 2024. We're fully through that backlog at this point. And then we also had some Q1 revenue that from an accounting standpoint was recognized in the second quarter. That being said, the underlying growth we saw in Q2 and the increase in both supply of product and demand, both with existing hospitals wanting to increase their penetration of IFC as well as new hospitals onboarding, it's quite a strong pipeline. And so that's what led us to raising the guidance for the full year and our belief and confidence that we'll continue to see both an inflow of new hospital customers in Q3 and Q4 as well as increasing depth with existing customers. Probably the biggest driver of that being now that we have a much more comfortable supply position entering the back half of the year.

Got it. Super helpful. And then I guess one more for me on OpEx. I guess, can you kind of parse out how much of the step-up reflects variable investment in growth versus, I guess, any one-time related spend? And I guess, how we should be thinking about expense cadence in the back half of the year?

Yes, Matt, not so much one-time related spend. I think we are seeing an increase in government contract activity underwritten by BARDA, FDA, and DoD, and you'll see that corresponding increase in government contract revenue. So certainly, that's a component of the increase in R&D expense. And then as mentioned in the prepared remarks, we did see cost of living adjustments for our employees consistent with what you see with other companies, just given the inflationary environment that we've had to operate in the last few years.

This concludes the question-and-answer session. I would now like to turn it back over to Mr. Greenman for closing remarks.

Thank you again for joining us today and for your interest in Cerus. We look forward to keeping you informed of our progress throughout the rest of 2025 through quarterly calls and investor conferences. Thanks again.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.